预约演示
更新于：2026-08-19
Ciprofloxacin Hydrochloride
盐酸环丙沙星
更新于：2026-08-19
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C17H21ClFN3O4 |
InChIKeyARPUHYJMCVWYCZ-UHFFFAOYSA-N |
CAS号86393-32-0 |
关联
36
项与 盐酸环丙沙星 相关的临床试验NCT06798402
Effectiveness of Ciprofloxacin Intralesional Injection in the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate: a Parallel Groups Comparative Trial
CTIS2024-513465-39-00
Clinical Efficacy of oral Fosfomycin Trometamol and Cefixime in the Treatment of Acute Bacterial Prostatitis (CEFOSPROST): a comparative, randomized, open, multicenter trial.
NCT06342830
Comparison of the Effects of Different Natural and Synthetic Intracanal Medicaments on the Healing of Periapical Lesion in Retreatment Cases (A Randomized Clinical Trial)
100 项与 盐酸环丙沙星 相关的临床结果
登录后查看更多信息
100 项与 盐酸环丙沙星 相关的转化医学
登录后查看更多信息
100 项与 盐酸环丙沙星 相关的专利（医药）
登录后查看更多信息
41,566
项与 盐酸环丙沙星 相关的文献（医药）2026-10-01TALANTA
Smartphone-assisted on-site detection of ciprofloxacin hydrochloride in coastal zone water using a one-pot synthesized molecularly imprinted ratiometric fluorescent sensor
Article
作者: Peng, Siyuan ; Ming, Yongfei ; Li, Jinhua ; Qi, Ji ; Liu, Ping ; Yan, Jingyi ; Song, Zhihua ; Chen, Lingxin ; Qiu, Zihan ; Sun, Dani
Coastal zones, characterized by intensive human activities, face dynamic contamination from emerging pollutants such as antibiotics. Hence, rapid on-site detection is crucial for acquiring real-time and accurate concentrations. Herein, a smartphone-assisted molecularly imprinted ratiometric fluorescent (MI-RFL) sensor was developed for on-site detection of ciprofloxacin hydrochloride (CPFX) in coastal zone water samples. A facile one-pot sol-gel surface imprinting approach was employed to construct the sensor using CPFX as the template, silica nanoparticles as the carrier, and gold nanoclusters (AuNCs) as the fluorescent element. CPFX exhibited intrinsic blue fluorescence emission, which, upon being captured by the molecularly imprinted layer, quenched the red fluorescence of the embedded AuNCs, thereby establishing a ratiometric fluorescence sensing mechanism. Meanwhile, the overall fluorescence displayed a distinct and high-resolution color transition from orange to blue. The MI-RFL sensor attained excellent analytical performance, including a wide linear range (0.1-20 ppm), low detection limit (0.028 ppm), and high selectivity toward CPFX. Moreover, when applied to coastal water samples, the sensor allowed rapid on-site detection of CPFX, showing satisfactory recoveries of 91.28-108.23% with relative standard deviations (RSDs) below 3.35%. Moreover, through the acquisition of fluorescent signals and subsequent data processing, the smartphone-assisted visual detection platform based on this sensor exhibited satisfactory sensitivity, which confirmed that smartphone-based systems can enable reliable quantitative analysis. The readily performed MI-RFL sensing study with simplified synthesis, improved batch-to-batch reproducibility and strong potential for scalable and industrialized production, demonstrated its promising practicality for on-site monitoring contamination in complex matrices.
2026-08-01ANNALS OF PHARMACOTHERAPY
Comment: Olanzapine Versus Quetiapine: Corrected QT Changes in Critically Ill Patients
Letter
作者: DeGrado, Jeremy R. ; Shen, Kaden ; Dube, Kevin M. ; Szumita, Paul M. ; Lupi, Kenneth E.
Background:: Olanzapine and quetiapine are frequently administered atypical antipsychotic medications and their effects on the corrected QT (QTc) in the critically ill population remain understudied.Objective:: The objective of this study was to compare the impact of olanzapine and quetiapine on QTc changes in critically ill patients.Methods:: This was a single-center, retrospective anal.Adult patients admitted to the intensive care unit (ICU) from Jan. 2023 through July 2023 were included if they received ≥2 doses of either olanzapine or quetiapine within a 48-h period and had one QTc evaluated within 48 h of antipsychotic initiation.The major endpoint was a composite of the incidence of QTc prolongation (defined as QTc > 500 ms or QTc > 60 ms above baseline) following antipsychotic initiation.Univariable and multivariable analyses were performed to identify risk factors for QTc prolongation.Results:: There was no statistical difference in the major composite endpoint between patients in the olanzapine and quetiapine groups (8/83 [9.6%] vs 19/129 [14.7%]; P = .28).The incidence of QTc > 500 ms (7/244 [2.9%] vs 20/427 [4.7%]; P = .25) and change from baseline >60 ms (5/244 [2.0%] vs 17/427 [4.0%]; P = .26) were not statistically different between the olanzapine and quetiapine groups, resp.There were no occurrences of Torsades de Pointes or extrapyramidal symptoms in either group.Conclusion and Relevance:: The results of this study suggest olanzapine and quetiapine may have similar impact on QTc prolongation in critically ill patients.These findings could contribute to safer prescribing practices in the ICU.
2026-07-07Microbiology Spectrum
Association of gut microbiota and inflammatory markers with enteral nutrition intolerance in patients with early-stage moderate-to-severe intracerebral hemorrhage
Article
作者: Zhu, Fei ; Zeng, Wei ; Cao, Demao ; Ding, Xuyuan ; Wang, Youwe ; Peng, Aijun ; Wu, Chenyi ; Jiang, Haixiao ; Zhang, Hengzhu ; Wang, Jiahao
ABSTRACT:
Enteral nutrition intolerance (ENI) is a common and challenging complication in patients with moderate-to-severe intracerebral hemorrhage (msICH). Emerging evidence suggests that gut microbiota is vital for host immune regulation and nutrient metabolism. However, the relationship between intestinal microbial alterations, inflammatory responses, and ENI in patients with early-stage msICH (emsICH) remains poorly understood. Therefore, this study aimed to explore these associations. A total of 100 patients with emsICH were enrolled in this study, including 50 with ENI and 50 without ENI (NENI). The gut microbiota composition was assessed using 16S ribosomal RNA gene sequencing, and the relationships between microbial profiles, systemic inflammatory indicators, and ENI status were systematically analyzed. Patients with ENI exhibited significantly reduced alpha diversity and distinct microbial structure when compared to those with NENI. Linear discriminant analysis effect size identified 19 differentially abundant taxa, with pathogenic genera, including
Enterococcus
and
Finegoldia
, enriched in patients with ENI. However, beneficial short-chain fatty acid-producing genera, such as
Subdoligranulum
and
Faecalibacterium
, were enriched in patients with NENI. A six-genus biomarker panel demonstrated a strong predictive power for ENI (area under the curve = 0.812). Functional phenotype analysis revealed an increased abundance of Gram-negative and facultative anaerobic bacteria in patients with ENI. Moreover, ENI-associated genera were positively correlated with blood inflammatory indicators, whereas NENI-associated taxa exhibited negative correlations. The analysis of the Kyoto Encyclopedia of Genes and Genomes pathways suggested that several essential physiological pathways in ENI were disturbed, with upregulation of inflammation-related signaling pathways (e.g., Jak-STAT and MAPK) and downregulation of pathways involved in metabolism (particularly in energy metabolism). Gut microbiota dysbiosis in patients with emsICH is strongly associated with ENI and systemic inflammation. Specific microbial signatures may serve as non-invasive biomarkers for ENI risk assessment. These findings shed light on gut microbiota-associated inflammation and the ENI axis and offer a theoretical basis for microbiota-targeted and nutritional interventions in neurocritical care.
IMPORTANCE:
Enteral nutrition intolerance (ENI) is a frequent and serious complication in patients with moderate-to-severe intracerebral hemorrhage (ICH). Our study demonstrates that ENI is strongly associated with gut microbiota imbalance, characterized by an overrepresentation of inflammation-promoting bacteria and a loss of beneficial short-chain fatty acid-producing taxa. This microbial shift was closely linked to heightened systemic inflammation, providing new insights into the gut-inflammation-ENI axis in neurocritical illness. By identifying specific bacterial signatures, our findings suggest that stool-based microbial assessment may serve as a noninvasive tool for early risk prediction and highlight the potential of microbiota-targeted strategies to improve nutritional management and outcomes in patients with ICH.
100 项与 盐酸环丙沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 鼠疫 | 美国 | 2015-02-02 | |
| 鼠疫 | 美国 | 2015-02-02 | |
| 细菌性前列腺炎 | 澳大利亚 | 2009-05-20 | |
| 支气管疾病 | 澳大利亚 | 2009-05-20 | |
| 胃肠炎 | 澳大利亚 | 2009-05-20 | |
| 淋菌性尿道炎 | 澳大利亚 | 2009-05-20 | |
| 宫颈炎 | 澳大利亚 | 2009-05-20 | |
| 复杂的尿路感染 | 美国 | 2004-03-25 | |
| 复杂的尿路感染 | 美国 | 2004-03-25 | |
| 膀胱炎 | 美国 | 2004-03-25 | |
| 膀胱炎 | 美国 | 2004-03-25 | |
| 痢疾 | 美国 | 2004-03-25 | |
| 痢疾 | 美国 | 2004-03-25 | |
| 淋病 | 美国 | 2004-03-25 | |
| 淋病 | 美国 | 2004-03-25 | |
| 伤寒 | 美国 | 2004-03-25 | |
| 伤寒 | 美国 | 2004-03-25 | |
| 炭疽 | 中国 | 2000-12-31 | |
| 细菌性结膜炎 | 美国 | 1998-03-30 | |
| 感染 | 中国 | 1991-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 支气管扩张 | 临床1期 | 德国 | 2012-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 412 | 膚鹹遞夢窪顧獵鹽淵夢(鹹壓網醖網選製憲鹽夢) = 夢蓋壓製淵蓋鏇鏇構繭 遞願獵衊製窪築構齋積 (鏇鹹築構膚廠築憲鹽夢 ) 更多 | 积极 | 2026-02-18 | |||
蓋遞糧壓繭壓觸膚獵蓋(夢糧襯構淵餘獵醖網鏇) = 衊鹽鬱齋範膚齋繭壓齋 製餘製醖窪廠顧簾窪觸 (鬱積鏇鏇鏇繭鑰廠獵餘 ) | |||||||
临床3期 | 493 | 憲憲齋獵築糧窪廠鑰鏇 = 廠襯繭衊膚獵積顧簾鏇 積糧鹽衊夢簾鏇鑰鬱繭 (齋衊獵觸積範鑰夢艱觸, 餘夢構鏇築鬱範鑰鹹製 ~ 艱衊憲願繭齋網醖淵鏇) 更多 | - | 2021-04-09 | |||
(DF289) | 憲憲齋獵築糧窪廠鑰鏇 = 鏇製築構窪觸蓋餘窪製 積糧鹽衊夢簾鏇鑰鬱繭 (齋衊獵觸積範鑰夢艱觸, 願膚淵顧觸網衊簾襯壓 ~ 築醖鹹憲餘齋蓋衊顧齋) 更多 | ||||||
临床3期 | 33 | ciprofloxacin | 鏇觸構簾繭製鑰艱觸鏇 = 範願壓窪遞衊蓋築襯艱 觸積膚齋鹽顧襯顧鹹積 (繭鑰襯壓蓋鑰夢窪艱鹹, 醖觸餘窪夢築衊壓獵窪 ~ 獵壓糧築鹹壓構鹽築廠) 更多 | - | 2020-09-23 | ||
临床2期 | 39 | 積艱網憲醖壓衊衊膚網 = 餘顧獵糧獵衊願糧壓蓋 顧選壓鹹鬱艱構範繭製 (鹽觸廠積膚醖顧選積窪, 鬱構鹽遞鏇選糧醖壓壓 ~ 積鹽襯憲範鹹艱積艱醖) 更多 | - | 2020-09-23 | |||
临床1期 | 26 | Ciprofloxacin (Ciprofloxacin 500 mg Reference) | 衊膚鏇鑰鬱願衊構糧觸(鏇構鹹築築艱艱網鏇簾) = 鬱範廠醖襯蓋鑰壓願遞 糧繭製獵顧鏇醖窪蓋鏇 (構網製淵遞築鏇製繭鏇, 22.5) 更多 | - | 2018-12-19 | ||
GR37547 (GR37547 500 mg) | 衊膚鏇鑰鬱願衊構糧觸(鏇構鹹築築艱艱網鏇簾) = 淵淵顧網醖憲淵遞襯觸 糧繭製獵顧鏇醖窪蓋鏇 (構網製淵遞築鏇製繭鏇, 27.7) 更多 | ||||||
临床4期 | 31 | Placebo (Placebo) | 積構廠製積願壓醖範範(築顧艱夢遞鑰網範遞醖) = 獵構遞鬱窪蓋鬱窪餘襯 艱鹹壓醖願遞積醖衊選 (簾顧觸簾糧獵醖遞繭鹽, 0.6) 更多 | - | 2017-01-23 | ||
(Ciprofloxacin Hydrochloride) | 積構廠製積願壓醖範範(築顧艱夢遞鑰網範遞醖) = 糧鏇簾積壓積鹹糧鬱膚 艱鹹壓醖願遞積醖衊選 (簾顧觸簾糧獵醖遞繭鹽, 0.59) 更多 | ||||||
临床3期 | 266 | (OTO-201) | 蓋廠廠衊簾觸壓齋鹹築 = 鹽衊夢衊淵選鏇製網襯 膚餘蓋鹽壓衊繭遞糧醖 (齋顧鬱壓窪艱衊遞顧蓋, 築築膚鬱築窪襯鹽憲壓 ~ 願夢鏇鹹遞衊鏇壓廠齋) 更多 | - | 2016-11-11 | ||
Sham (Sham) | 蓋廠廠衊簾觸壓齋鹹築 = 構窪憲艱獵選網壓艱繭 膚餘蓋鹽壓衊繭遞糧醖 (齋顧鬱壓窪艱衊遞顧蓋, 鹽淵醖鬱築蓋糧鏇鏇鑰 ~ 艱餘積衊淵醖齋膚齋構) 更多 | ||||||
临床3期 | 331 | (DF289) | 糧夢遞觸鑰獵夢壓淵艱(醖網獵醖廠齋積獵鬱觸) = 製餘膚範願選糧範網糧 鹽齋鏇醖觸鏇積鬱夢衊 (襯觸鑰壓醖憲醖範鬱範, 鹽構鹹鹹範願淵壓衊鬱 ~ 網齋簾膚顧鹽夢蓋衊壓) 更多 | - | 2015-11-23 | ||
(DF277) | 糧夢遞觸鑰獵夢壓淵艱(醖網獵醖廠齋積獵鬱觸) = 築製顧獵範觸壓鹽憲憲 鹽齋鏇醖觸鏇積鬱夢衊 (襯觸鑰壓醖憲醖範鬱範, 廠顧願簾遞憲廠壓壓繭 ~ 憲壓鹹願簾淵遞築範遞) 更多 | ||||||
临床3期 | 331 | (DF289) | 範構顧憲衊夢餘淵範衊(顧鹽膚醖淵製鹽願憲選) = 餘網鏇顧鬱憲醖窪鏇齋 膚膚醖襯鏇繭鏇夢顧襯 (膚觸糧鹹選積窪積衊願, 糧蓋窪襯淵醖鑰窪鑰鏇 ~ 餘壓齋夢鬱選壓鬱窪憲) 更多 | - | 2015-10-22 | ||
(DF277) | 範構顧憲衊夢餘淵範衊(顧鹽膚醖淵製鹽願憲選) = 憲繭簾觸齋簾遞鹽醖選 膚膚醖襯鏇繭鏇夢顧襯 (膚觸糧鹹選積窪積衊願, 憲構艱簾夢願窪選觸鹽 ~ 淵鹽餘網遞壓壓簾網網) 更多 | ||||||
临床2期 | 288 | (32.50 mg Ciprofloxacin DPI (BAYQ3939)) | 鹹鬱淵鑰網齋鏇鬱鬱觸(艱鏇獵範願衊鏇餘鏇繭) = 積鬱遞鹹醖鏇範網鑰鑰 範壓鬱醖襯簾壓遞齋夢 (獵築艱範築網鏇齋廠鹹, 6.01) 更多 | - | 2012-07-03 | ||
(48.75 mg Ciprofloxacin DPI (BAYQ3939)) | 鹹鬱淵鑰網齋鏇鬱鬱觸(艱鏇獵範願衊鏇餘鏇繭) = 醖鬱鹽廠遞願範淵淵膚 範壓鬱醖襯簾壓遞齋夢 (獵築艱範築網鏇齋廠鹹, 5.52) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用